Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 196

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 2
Chunk 196
---
 months ended June 30, 2025. The period-over-period increase was primarily related to an increase in personnel-related costs, professional fees, and other expenses as we continue to build our commercial organization. 

Other income 

Other income for the three months ended June 30, 2025, was $147.9 million compared to other income of $3.9 million for the three months ended June 30, 2024. The increase was primarily attributable to the gain on sale of the PRV of $148.3 million and the decrease in fair value adjustment related to warrant and CVR liability of $6.5 million.

37

Comparison of the six months ended June 30, 2025, and 2024 (in thousands):

Six months ended June 30,Period-to-20252024Period ChangeRevenue, net$46,282 $7,874 $38,408 Cost of product revenue (excluding $3,231 and $3,074 in intangible asset amortization for the six months ended June 30, 2025, and 2024, respectively, shown separately below)13,724 3,748 9,976 Intangible asset amortization3,231 3,074 157 Impairment of intangible assets58,710 — 58,710 Operating expenses:Research and development6,691 22,798 (16,107)Selling, general and administrative40,327 22,535 17,792 Total operating expenses47,018 45,333 1,685 Loss from operations(76,401)(44,281)(32,120)Other income (expense):Gain on sale of PRV148,325 — 148,325 Interest expense(3,978)(2,845)(1,133)Fair value adjustment related to warrant and CVR liability4,127 9,406 (5,279)Fair value adjustment related to investments(5)(26)21 Interest and other income, net2,921 1,199 1,722 Total other income151,390 7,734 143,656 Income (loss) before income taxes74,989 (36,547)111,536 Income tax expense(3,381)— (3,381)Net income (loss)$71,608 $(36,547)$108,155 

Net Income (Loss)

Net income for the six